ASG Webinar Series

We’re excited to kick off the 2025 Webinar Series with our very first session—part of our ongoing commitment to education, collaboration, and professional development within the Alberta GI community.

By the end of the webinar series participants will be able to:


  • Compare and contrast therapeutic approaches in the care of patients with a wide variety of gastrointestinal diseases
  • Articulate the key findings of current research into objective monitoring for patients with IBD, Liver, and luminal GI disorders
  • Distill the latest and most salient information in recent publications and presentations
  • Foster physician wellness and a provincial community of practice

Session 2:What is the Future of IBD Therapeutics?

Date & Time: Monday, October 27 at 5:30 PM MT

Presenter:
Dr. Christopher Ma

Associate Professor, University of Calgary, Gastroenterologist, Alberta Health Services.

By the end of this session participants will be able to:

  • Discuss the current state of advanced therapies for IBD and what we can expect in the next 10 years
  • Identify emerging therapeutic targets and novel mechanisms of action in the treatment of IBD
  • Evaluate how future developments in precision medicine and biomarkers may influence personalized treatment strategies for IBD patients; 


This webinar will be followed by a Symposium sponsored by Johnson & Johnson. More details will follow shortly.


Register Here


Session 3: Celiac Disease: Beyond the Gluten-Free Diet

Date & Time: Tuesday, November 18 at 5:30 PM MT

Presenter:
Dr. Benjamin Lebwohl

Professor of Medicine and Epidemiology, Columbia Univeristy Medical Center, Director of Clinical Research, The Celiac Disease Center at Columbia University.


Moderator:
Dr. Gill Kaplan

Professor of Medicine & Community Health Sciences, University of Calgary Scientific  Director, Digestive Health Stratigic Clinical Network, Alberta Health Services, Gastroenterologist, Alberta Health Services. 


By the end of this session participants will be able to:

  • Describe globals trends in the epidemiology and diagnosis of celiac disease, including rising incidence rates and patterns of underdiagnosis across diverse populations.
  • Distinguished celiac disease from other conditions with overlapping clinical or historical features, such as isolated gliadin-peptide elevation and non non-celiac villus atrophy
  • Evaluate emerging non-dietary therapeutic strategies and clinical trial designs for celiac disease, with a focus on endpoint selection and regulatory consideration.


Register Here


Session 1: Barrett's Esophagus
Date & Time: Monday, May 20 at 5:30 PM MT

Presenter:
Dr. Clarence Wong, 

Professor and Director, Division of Gastroenterology, University of Alberta


Moderator:
Dr. Milli Gupta, 

Associate Clinical Professor of Medicine, Division of Gastroenterology and Hepatology University of Calgary


By the end of this session participants will be able to:

  • List the pathophysiology and risk factors associated with the development of Barrett's esophagus.

  • Recognize the common symptoms and diagnostic criteria used to identify Barrett's esophagus in patients.

  • Analyze available therapeutic interventions for managing Barrett's esophagus.

Register Here


This webinar has received an educational grant or in-kind support from:


Pfizer, AbbVie, Celltrion, Johnson & Johnson, Takeda, Lilly, Ipsen, Gilead, Amgen, Organon, Merck, Pentax, GSK, Ferring Pharmaceuticals, Fresenius-Kabi, Sanofi, Boston Scientific, Avir Pharma, Cencora Innomar Strategies. Sandoz, Pendopharm, Lupin